Medtronic
As of the edition of 20 October 2026, Medtronic runs 5 drugs, 5 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 16 company names in this family.
- Medtronic MiniMed, Inc.: acquired in 2001; successor Medtronic, Inc.
- Osteotech, Inc: acquired in 2010; successor Medtronic, Inc.
- Covidien: acquired in 2015; successor Medtronic, Inc.
- Intersect ENT: acquired in 2022; successor Medtronic, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Mometasone furoate | none listed | 3 |
| Baclofen | none listed | 1 |
| Mometasone | none listed | 3 |
| Isosulfan blue inner salt | none listed | 0 |
| Dibotermin alfa | none listed | 0 |
A route B row is one company at one target.